Log in or register to see all Alerts
New HTA Decisions in England
October 2021
Drug name
XOFLUZA® (baloxavir marboxil)
Company
Roche
Decision date
//
Therapeutic area
Infections
Therapeutic sub area
Influenza
Decision
Not recommended
Indication
Acute uncomplicated influenza.
Decision Detail
Terminated appraisal.
Summary
NICE is unable to make a recommendation about the use in the NHS of baloxavir marboxil for treating acute uncomplicated influenza. Roche considers that there is not enough evidence to provide an evidence submission for this appraisal. NICE will review the position if the company decides that it wants to make an evidence submission.